S. Chasan-Taber

发表

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

D. Gaudet, F. Raal, R. Santos, 2010, The Lancet.

Reproducibility and Validity of a Self‐Administered Physical Activity Questionnaire for Male Health Professionals

E. Rimm, G. Colditz, D. Spiegelman, 1996, Epidemiology.

Determinants of progressive vascular calcification in haemodialysis patients.

P. Raggi, G. Chertow, S. Chasan-Taber, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Results of a phase Iii trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea

S. Chasan-Taber, E. Bouza, M. Dryden, 2008 .

Decrease in Thoracic Vertebral Bone Attenuation With Calcium‐Based Phosphate Binders in Hemodialysis

P. Raggi, G. Chertow, S. Chasan-Taber, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Quality of care for two common illnesses in teaching and nonteaching hospitals.

J. Weissman, A. Epstein, S. Chasan-Taber, 1998, Health affairs.

The influence of health-related quality of life and social characteristics on hospital use by patients with AIDS in the Boston Health Study.

C. Gatsonis, P. Cleary, J. Haas, 1996, Medical care.

Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?

P. Raggi, G. Chertow, S. Chasan-Taber, 2002, Journal of the American College of Cardiology.

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

S. Chasan-Taber, S. Fan, P. Kalra, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.

P. Raggi, G. Chertow, S. Chasan-Taber, 2005, Arthritis and rheumatism.

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

S. Chasan-Taber, J. Delmez, G. Block, 2007, Clinical nephrology.

Quality of care by race and gender for congestive heart failure and pneumonia.

J. Weissman, A. Epstein, S. Chasan-Taber, 1999, Medical care.

The validity of self‐reported health‐care utilization by AIDS patients

M. Massagli, J. Weissman, S. Chasan-Taber, 1996, AIDS.

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

W. Suki, S. Chasan-Taber, S. Moe, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals.

E. Rimm, W. Willett, G. Colditz, 1998 .

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

P. Raggi, G. Chertow, S. Chasan-Taber, 2005, American heart journal.

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

T. Louie, D. Gerding, S. Chasan-Taber, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

T. Louie, S. Chasan-Taber, G. Garber, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

W. Suki, S. Chasan-Taber, S. Burke, 2007, Kidney international.

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

J. Tardif, S. Chasan-Taber, G. Wagener, 2012, PloS one.

Reproducibility of a self-administered lifetime physical activity questionnaire among female college alumnae.

P. Freedson, P. Nasca, S. Chasan-Taber, 2002, American journal of epidemiology.

Validity and reproducibility of a physical activity questionnaire in women.

P. Freedson, P. Nasca, S. Chasan-Taber, 2002, Medicine and science in sports and exercise.

Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.

J. Kremer, M. Weisman, D. Furst, 1998, Arthritis and rheumatism.

End-Stage Renal Disease Cardiac Calcification in Adult Hemodialysis Patients

G. Chertow, S. Chasan-Taber, S. Burke, 2016 .

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

S. Chasan-Taber, R. Selgas, S. Fan, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

W. Suki, S. Chasan-Taber, S. Moe, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA

J. Tardif, S. Chasan-Taber, G. Wagener, 2011 .

Hospital readmissions and quality of care.

J. Weissman, A. Epstein, M. Sherwood, 1999, Medical care.